Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

  • End date
    Sep 1, 2027
  • participants needed
  • sponsor
    National Cancer Institute (NCI)
Updated on 24 July 2022
flow cytometry
granulocyte colony stimulating factor
bone marrow procedure
colony stimulating factor
neutrophil count
b-cell lymphoma
fludeoxyglucose f-18



Aggressive B-cell lymphomas can be cured but people with disease that resists treatment or that returns after treatment have poor outcomes with standard therapies. Indolent B-cell lymphomas are generally incurable with standard therapy and treatment is aimed at controlling symptoms and achieving a durable remissions. Researchers want to see if a combination of drugs can help patients with both aggressive and indolent B-cell lymphomas.


To learn if it is safe and effective to give polatuzumab along with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide to people with certain B-cell lymphomas.


Adults ages 18 and older with relapsed and/or refractory B-cell lymphoma who have had at least one prior cancer treatment.


Participants will be screened with:

Medical history

Physical exam

Assessment of how they do their daily activities

Blood and urine tests

Heart function test

Tissue biopsy (if needed)

Body imaging scans (may get a contrast agent through an intravenous (IV) catheter)

Participants will have a bone marrow aspiration and/or biopsy. A needle will be put into the hipbone. Bone marrow will be removed.

Participants may give blood, tissue, saliva, or cheek swab samples. They may have optional biopsies.

Screening tests will be repeated during the study.

Treatment will be given for up to 6 cycles. Each cycle lasts 21 days.

Participants will take venetoclax and prednisone tablets by mouth. They will take ibrutinib and lenalidomide capsules by mouth. They will get obinutuzumab and polatuzumab by IV infusion. They will keep a medicine diary.

Participants will visit the clinic 30 days after treatment ends. They will have follow-up visits for 5 years. If needed, they can visit their local doctor instead. They may be contacted by phone, mail, etc., for the rest of their life....


  • Combination chemotherapy with rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas.
  • Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas and relapsed/refractory aggressive lymphomas remain mostly incurable with chemotherapy alone.
  • Targeted therapies, aimed at disrupting key survival pathways in lymphoid malignancies, are emerging and showing significant activity in non-Hodgkin lymphoma (NHL) in both the relapsed and first-line settings.
  • Mechanistically based combinations of targeted agents are likely to benefit patients who cannot tolerate or who relapse after or are refractory to standard chemoimmunotherapy.
  • ViPOR-P targets major survival pathways in B-cell lymphomas including BCL-2 (apoptosis); BTK (B-cell receptor signaling and NF-kB); Cereblon (NF-kB) and CD20 with additional genotoxic stress from the anti-mitotic antibody-drug conjugate targeting CD79b, polatuzumab.

To determine the maximum tolerated dose (MTD) and the safety and toxicity profile of polatuzumab and venetoclax in combination with venetoclax, ibrutinib, prednisone, obinutuzumab and Revlimid(SqrRoot) (lenalidomide) (ViPOR-P) in relapsed/refractory B-cell lymphomas

  • Women and men greater than or equal to 18 years of age
  • ECOG performance status of less than or equal to 2
  • Histologically or cytologically confirmed relapsed and/or refractory B-cell lymphoma, excluding mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
  • Adequate organ function unless dysfunction secondary to lymphoma
  • Open-label, single-center, non-randomized phase 1 study
  • Standard 3 + 3 design will be used to determine the MTD of polatuzumab and venetoclax in combination with venetoclax, ibrutinib, prednisone, obinutuzumab and Revlimid (lenalidomide) (ViPOR-P) in relapsed/refractory B-cell lymphomas
  • A small expansion cohort will be treated at the MTD in a further analysis of safety and preliminary activity.
  • Maximum 6 cycles of combination targeted therapy every 21 days.
  • To explore all dose levels in the phase 1 study and to allow for the possibility of a few screen failures and inevaluable subjects, the accrual ceiling will be set at 32 patients.

Condition Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
Treatment prednisone, Ibrutinib, Obinutuzumab, venetoclax, Revlimid, Polatuzumab
Clinical Study IdentifierNCT04739813
SponsorNational Cancer Institute (NCI)
Last Modified on24 July 2022


Yes No Not Sure

Inclusion Criteria

Patients must have histologically or cytologically confirmed B-cell lymphoma confirmed by the Laboratory of Pathology, NCI, as follows
Aggressive B-cell lymphoma: includes DLBCL and subtypes, transformed lymphoma, Burkitt lymphoma, as well as high-grade B-cell lymphoma with MYC and/or BCL2 and/or BCL6 rearrangement(s)
Indolent B-cell lymphoma: with the following exceptions
MCL is excluded given increased risk of tumor lysis syndrome (TLS) with venetoclax compared to other non-Hodgkin lymphomas and need for venetoclax ramp-up, dose-escalation
CLL/SLL is excluded given alternative dosing of FDA-approved venetoclax for relapsed CLL/SLL and increased risk of TLS with CLL/SLL compared to other non-Hodgkin lymphomas
NOTE: Patients with known active CNS lymphoma are not eligible
Relapsed and/or refractory disease after at least 1 prior treatment regimen, as
Aggressive B-cell lymphoma: relapsed after and/or refractory to at least 1 prior anthracycline-containing regimen
Indolent B-cell lymphoma: relapsed after and/or refractory to at least 1 prior anti- CD20 antibody-containing regimen
Patients must have evaluable disease by clinical exam (i.e., palpable lymphadenopathy
measurable skin lesions, etc.), laboratory assessment (i.e., lymphoma
involvement of bone marrow or peripheral blood by morphology, cytology or flow
cytometry), and/or imaging (measurable lymph nodes or masses on CT or MRI
Age greater than or equal to18 years
and/or evaluable FDG-avid lesions on PET)
NOTE: Lesions that have been irradiated cannot be included in the tumor assessment unless
unequivocal tumor progression has been documented in these lesions after radiation therapy
NOTE: Because no dosing or adverse event data are currently available on the use of
ECOG performance status less than or equal to 2
polatuzumab in combination with venetoclax, ibrutinib, obinutuzumab, prednisone and
Adequate organ and marrow function as defined below unless dysfunction is secondary to
Revlimid in patients <18 years of age, children are excluded from this study, but will be
eligible for future pediatric trials
absolute neutrophil count greater than or equal to 1,000/mcL
hemoglobin greater than or equal to 8 g/dL
Platelets greater than or equal to 75,000/mcL
AST(SGOT)/ALT(SGPT) less than or equal to 3 X institutional ULN
INR less than or equal to 1.5 X institutional upper limit of normal (ULN) for
Serum creatinine less than or equal to 2.0 mg/dL; OR
patients not receiving therapeutic anticoagulation
PTT/aPTT less than or equal to 1.5 X institutional ULN normal except if, in the
opinion of the investigator, the aPTT is elevated because of a positive Lupus
Anticoagulant, or a significant bleeding risk has been ruled out in the absence
of a positive Lupus Anticoagulant
total bilirubin less than or equal to 1.5 X institutional ULN (or less than or
For women of childbearing potential
equal to 3 X institutional ULN for patients with documented Gilberts syndrome
identified by an isolated unconjugated hyperbilirubinemia in the absence of other
signs of liver dysfunction and/or UGT1A1 mutational testing)
Creatinine clearance greater than or equal to 30 mL/min/1.73 m2 for patients with
creatinine levels above 2 mg/dL
For men
NOTE: Cr Cl will be calculated with the use of the 24-hour creatinine clearance or eGRF in
the clinical lab
RBC transfusions and use of G-CSF will be allowed in order to meet eligibility
Immune-modulating drugs (IMiDs) including Revlimid are known to be teratogenic
Contraception Requirements
and potential embryo-fetal harm can be seen with use of polatuzumab, venetoclax
and ibrutinib. The effects of obinutuzumab on the developing human fetus is
unknown. For these reasons, women of child-bearing potential and men must agree
to use adequate contraception as described below. Should a woman become pregnant
or suspect she is pregnant while she or her partner is participating in this
Post-Treatment/Venetoclax; Women - 90 days; Men - 90 days
study, she should inform her treating physician immediately
Post-Treatment/Ibrutinib; Women - 3 months; Men - 3 months
Post-Treatment/Obinutuzumab; Women - 18 months; Men - 6 months
Agreement to remain abstinent (refrain from heterosexual intercourse)
Post-Treatment/Revlimid; Women - 28 days; Men - 28 days
or use a contraceptive method with a failure rate of less than 1% per
Post-Treatment/Polatuzumab; Women - 3 months; Men - 5 months
year as outlined below
Agreement to refrain from donating eggs during timelines specified
Female subjects of childbearing potential (FCBP) must have a negative
serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL
within 10-14 days and again within 24 hours prior to prescribing
Revlimid for Cycle 1 (prescriptions must be filled within 7 days as
required by Revlimid REMSTM) and must either commit to continued
abstinence from heterosexual intercourse or begin TWO acceptable
methods of birth control, one highly effective method and one
additional effective method AT THE SAME TIME, at least 28 days before
she starts taking Revlimid FCBP must also agree to ongoing pregnancy
A woman is considered to be of childbearing potential if she is
post-menarcheal, has not reached a postmenopausal state (greater than
or equal to 12 continuous months of amenorrhea with no identified cause
other than menopause), and has not undergone surgical sterilization
(removal of ovaries and/or uterus)
Examples of contraceptive methods with a failure rate of less than 1%
per year include bilateral tubal ligation, male sterilization, hormonal
contraceptives that inhibit ovulation, hormone-releasing intrauterine
devices, and copper intrauterine devices
The reliability of sexual abstinence should be evaluated in relation to
the duration of the clinical trial and the preferred and usual
lifestyle of the patient. Periodic abstinence (e.g., calendar
ovulation, symptothermal, or post-ovulation methods) and withdrawal are
not acceptable methods of contraception
Agreement to remain abstinent (refrain from heterosexual intercourse)
or use contraceptive measures, and agreement to refrain from donating
sperm, as defined below
With female partners of childbearing potential, men must remain
abstinent or use a condom plus an additional contraceptive method that
together result in a failure rate of less than 1% per year as noted
below. Men must refrain from donating sperm during this same period
With pregnant female partners, men must remain abstinent or use a
condom as noted below to avoid exposing the embryo
The reliability of sexual abstinence should be evaluated in relation to
the duration of the clinical trial and the preferred and usual
lifestyle of the patient. Periodic abstinence (e.g., calendar
ovulation, symptothermal, or post-ovulation methods) and withdrawal are
not acceptable methods of contraception
Time frame/Study Drug (Pre-Treatment/During Treatment) - Women/Men (Time
frame prior to/during dosing)
-- Pre-Treatment/During Treatment/All drugs; Women - Begins 28 days prior
to treatment; Men - Begins on day 1
Time frame/Study Drug (Post-Treatment) - Women/Men (Time frame after the
last dose)
All study participants must be registered into the mandatory Revlimid REMSTM
program and be willing and able to comply with the requirements of Revlimid
REMSTM. NOTE: Females of reproductive potential must adhere to the scheduled
pregnancy testing as required in the Revlimid REMSTM program
Ability of subject to understand and the willingness to sign a written informed
consent document

Exclusion Criteria

Patients who are actively receiving any other investigational agents
Radio- or toxin-immunoconjugates within 10 weeks
Strong CYP3A inhibitors within 7 days
Strong CYP3A inducers within 7 days
Uncontrolled and/or symptomatic thyroid disease
Evidence of active tumor lysis syndrome based on laboratory assessment
The following restrictions apply to current or prior anti-cancer treatment, prior to
the first dose of study drug
Any chemotherapy or anti-cancer antibodies within 2 weeks. NOTE: Short courses of
corticosteroids or palliative XRT prior to enrollment are permitted within the 2-
week washout period
Previous treatment with more than one of the other study agents (i.e
polatuzumab, venetoclax, ibrutinib, or Revlimid ), excluding prior prednisone or
anti-CD20 antibody treatment
Prior allogeneic stem cell (or other organ) transplant within 6 months or any
evidence of active graft-versus-host disease or requirement for
immunosuppressants within 28 days
Not recovered (i.e., less than or equal to Grade 1 or baseline) from adverse
events due to previously administered anti-cancer treatment, surgery, or
procedure. NOTE: Exceptions to this include events not considered to place the
subject at unacceptable risk of participation in the opinion of the PI (e.g
Patients requiring the use of warfarin are excluded because of potential drug-drug
interactions that may potentially increase the exposure of warfarin
Patients requiring the following agents to the first dose of venetoclax or ibrutinib
are excluded, as noted
NOTE: Moderate CYP3A inhibitors and inducers should be used with caution and an alternative
medication used, whenever possible
Uncontrolled intercurrent illness including, but not limited to the following that may
limit interpretation of results or that could increase risk to the patient at the
discretion of the inves0tigator
Symptomatic congestive heart failure, unstable angina pectoris, or uncontrolled
cardiac arrhythmia
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other
infection (excluding fungal infections of nail beds) at study enrollment, or any
major episode of infection requiring treatment with IV antibiotics or
hospitalization (relating to the completion of the course of antibiotics) within
weeks prior to Cycle 1, Day 1
Clinically significant history of liver disease, including viral or other
hepatitis, current alcohol abuse, or cirrhosis; as well as active infection with
Patients who are positive for HCV antibody must be negative for HCV by
polymerase chain reaction (PCR) to be eligible for study participation
Patients with occult or prior HBV infection (defined as positive total
hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV
DNA is undetectable (i.e., none detected in copies/mL or IU/mL). These
patients must be willing to undergo monthly DNA testing during treatment and
for at least 12 months after completion of study therapy
Malabsorption syndrome or other condition that precludes enteral route of
Psychiatric illness/social situations that would limit compliance with study
Pregnant women, or women who intend to become pregnant during the study, are excluded
from this study because Revlimid has known teratogenic effects and polatuzumab
venetoclax, ibrutinib and obinutuzumab are agents with the potential for teratogenic
or abortifacient effects. Because there is an unknown but potential risk for adverse
events in nursing infants secondary to treatment of the mother with these agents
breastfeeding should be discontinued if the mother is treated on study
HIV-positive patients are ineligible because of the potential for pharmacokinetic
interactions with venetoclax, ibrutinib and Revlimid and combination antiretroviral
therapy. In addition, these patients are at increased risk of lethal infections when
treated with marrow-suppressive therapy. Appropriate studies will be undertaken in
patients receiving combination antiretroviral therapy when indicated
History of recent major surgery within 6 weeks prior to the start of Cycle 1, Day 1
other than for diagnosis
History of other active malignancy that could affect compliance with the protocol or
interpretation of results
Patients with a history of curatively treated basal or squamous cell carcinoma or
stage 1 melanoma of the skin as well as any in situ carcinoma are eligible
Patients with a malignancy that has been treated with curative intent will also
be eligible. Individuals in documented remission who are not receiving active
treatment prior to enrollment may be included at the discretion of the
Known allergy to both xanthine oxidase inhibitors and rasburicase; or, known
hypersensitivity to any of the study drugs
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note